Midamor

Polyuria, Ascites, Hypokalemia + 7 more

Treatment

5 FDA approvals

20 Active Studies for Midamor

What is Midamor

Amiloride

The Generic name of this drug

Treatment Summary

Amiloride is a drug used to prevent the loss of potassium in the body. It works by blocking the reabsorption of sodium in the kidneys, which in turn creates a negative charge that reduces the secretion of potassium and hydrogen ions. Amiloride is usually taken with other diuretics to increase its effectiveness.

Amiloride Hydrochloride

is the brand name

image of different drug pills on a surface

Midamor Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Amiloride Hydrochloride

Amiloride

1986

23

Approved as Treatment by the FDA

Amiloride, otherwise called Amiloride Hydrochloride, is approved by the FDA for 5 uses like Congestive Heart Failure (CHF) and Hypokalemia .

Congestive Heart Failure (CHF)

Used in combination with other therapies

Hypokalemia

Congestive Heart Failure

Used in combination with other therapies

kaliuretic diuretics

Hypertensive disease

Effectiveness

How Midamor Affects Patients

Amiloride is a medication used to treat high blood pressure and congestive heart failure. It is an antihypertensive, potassium-sparing diuretic, meaning it helps the body get rid of extra fluids while also helping to keep potassium levels in the blood normal. It is often taken together with other diuretics. High levels of potassium in the blood (hyperkalemia) can occur when taking amiloride, especially if it is combined with ACE inhibitors or spironolactone. People taking this drug should avoid using salt replacements that contain potassium.

How Midamor works in the body

Amiloride works by preventing sodium from being reabsorbed in the kidneys. This causes sodium and water to be excreted from the body, but it does not reduce potassium levels. Amiloride does this by blocking sodium channels in the distal convoluted tubules and collecting ducts. This reduces the negative charge in the tubular lumen, which stops potassium and hydrogen from being secreted. Amiloride does not need aldosterone to work.

When to interrupt dosage

The proposed dosage of Midamor is contingent upon the diagnosed state, including Metabolic Alkalosis, Bartter's syndrome and Congestive Heart Failure. The measure of dosage is subject to the method of delivery (e.g. Oral or Tablet) enumerated in the table underneath.

Condition

Dosage

Administration

Congestive Heart Failure

, 5.0 mg

, Tablet, Oral, Tablet - Oral

Hypertensive disease

, 5.0 mg

, Tablet, Oral, Tablet - Oral

Ascites

, 5.0 mg

, Tablet, Oral, Tablet - Oral

lithium

, 5.0 mg

, Tablet, Oral, Tablet - Oral

Bartter Syndrome

, 5.0 mg

, Tablet, Oral, Tablet - Oral

kaliuretic diuretics

, 5.0 mg

, Tablet, Oral, Tablet - Oral

Nephrolithiasis

, 5.0 mg

, Tablet, Oral, Tablet - Oral

Hypokalemia

, 5.0 mg

, Tablet, Oral, Tablet - Oral

Polyuria

, 5.0 mg

, Tablet, Oral, Tablet - Oral

Metabolic Alkalosis

, 5.0 mg

, Tablet, Oral, Tablet - Oral

Warnings

Midamor possesses four contraindications and should not be consumed in cases of the conditions identified in the table below.

Midamor Contraindications

Condition

Risk Level

Notes

Renal Insufficiency

Do Not Combine

Hyperkalemia

Do Not Combine

potassium supplementation

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Midamor.

Common Midamor Drug Interactions

Drug Name

Risk Level

Description

Cisplatin

Major

The serum concentration of Cisplatin can be increased when it is combined with Amiloride.

Clofarabine

Major

The serum concentration of Clofarabine can be increased when it is combined with Amiloride.

Cyclosporine

Major

The risk or severity of hyperkalemia can be increased when Amiloride is combined with Cyclosporine.

Dalfampridine

Major

The serum concentration of Dalfampridine can be increased when it is combined with Amiloride.

Gentamicin

Major

The serum concentration of Gentamicin can be increased when it is combined with Amiloride.

Midamor Toxicity & Overdose Risk

Taking too much amiloride hydrochloride can be dangerous, as the lethal dose in mice is 56 mg/kg and 36 to 85 mg/kg in rats. Signs of overdose include dehydration and an imbalance of electrolytes in the body.

Midamor Novel Uses: Which Conditions Have a Clinical Trial Featuring Midamor?

Presently, 53 active trials are being conducted to assess the utility of Midamor in treating Hypokalemia, Bartter's Syndrome and Congestive Heart Failure.

Condition

Clinical Trials

Trial Phases

Hypokalemia

0 Actively Recruiting

Congestive Heart Failure

13 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Hypertensive disease

30 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Nephrolithiasis

0 Actively Recruiting

kaliuretic diuretics

0 Actively Recruiting

Ascites

2 Actively Recruiting

Not Applicable, Phase 2

Polyuria

0 Actively Recruiting

Metabolic Alkalosis

0 Actively Recruiting

Bartter Syndrome

0 Actively Recruiting

lithium

0 Actively Recruiting

Midamor Reviews: What are patients saying about Midamor?

3.3

Patient Review

11/4/2015

Midamor for High Blood Pressure

I had a really bad reaction to this medication after consuming alcohol. I was vomiting for hours and ended up in the ER because I couldn't even drink water. They did an endoscopy and found that my throat had closed up. I'm now worried about the long-term side effects of this drug, as they mimic my existing eye conditions.

2.3

Patient Review

9/15/2012

Midamor for High Blood Pressure

I've been urinating frequently, and my muscles have become weak and uncoordinated. This product has not alleviated these issues at all.

Patient Q&A Section about midamor

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What type of diuretic is Midamor?

"Midamor is a water pill that helps prevent your body from absorbing too much salt and keeps your potassium levels from getting too low. It's used to treat or prevent hypokalemia (low potassium levels in the blood) in people with high blood pressure or congestive heart failure."

Answered by AI

Is Midamor a loop diuretic?

"MIDAMOR (amiloride) has been shown to decrease the enhanced urinary excretion of magnesium when used with a thiazide or loop diuretic. MIDAMOR (amiloride) also has potassium-conserving activity in patients receiving kaliuretic-diuretic agents."

Answered by AI

Does Midamor lower potassium?

"Amiloride may cause your body to retain potassium. This is especially likely if you have diabetes, take other diuretics, take medications that can increase potassium in the blood, or if you're over 65."

Answered by AI

What is Midamor used for?

"Amiloride is a medication used to help treat heart conditions like high blood pressure, heart failure, or fluid retention. It is often used in combination with other medications like diuretics and thiazide diuretics. Amiloride can also help to prevent low blood potassium levels that can be caused by other medications."

Answered by AI

Clinical Trials for Midamor

Image of University of California, San Diego in San Diego, United States.

BPCARE Intervention for High Blood Pressure

18+
All Sexes
San Diego, CA

The goal of this randomized clinical trial is to determine whether a community health worker-delivered, multi-component behavioral intervention can improve antihypertensive medication adherence and blood pressure control among adult refugees with hypertension who are prescribed antihypertensive medications. The main questions it aims to answer are: 1. Does participation in the BPCARE intervention improve antihypertensive medication adherence compared to enhanced usual care? 2. Does participation in the BPCARE intervention improve blood pressure control and persistence over time compared to enhanced usual care? Researchers will compare participants randomized to the BPCARE intervention to those receiving enhanced usual care (hypertension information and a home blood pressure monitor) to determine the effects on medication adherence, blood pressure control, and persistence. Participants will: * Be randomly assigned to either the BPCARE intervention or enhanced usual care * Receive hypertension education and a home blood pressure monitor * Participate in community health worker-delivered sessions that include hypertension and medication education, motivational interviewing, problem-solving, and action planning (intervention arm only) * Complete questionnaires assessing medication adherence and related psychosocial factors * Have blood pressure monitored using connected home blood pressure devices * Complete pill counts to assess medication adherence over a nine-month follow-up period

Recruiting
Has No Placebo

University of California, San Diego (+1 Sites)

Image of National Association of Pasifika Organizations in Fayetteville, United States.

PILI Pasifika Program for Cardiometabolic Conditions

18+
All Sexes
Fayetteville, AR

In this study, the investigators are testing the effectiveness and implementation of the Community Health Workers (CHW)-delivered PILI Pasifika Program (PPP) Standard Facilitation or Enhanced Facilitation across 3 regions, the U.S. Affiliated Pacific Islands (USAPI), the continental U.S., and Hawai'i, among 600 Native Hawaiian and Pacific Islander (NHPI) participants in two settings, (clinical and non-clinical) over a 3-year period. The PPP is a 3-month lifestyle intervention that includes a Social Determinants of Health (SDOH) component and was NHPI-adapted from the Diabetes Prevention Program's Lifestyle Program, renamed to the PILI Lifestyle Program (PLP), which demonstrated effectiveness in improving weight, blood pressure, physical activity, and diet among NHPIs. The PPP consists of 8 lifestyle lessons and 4 SDOH activities delivered over a 3-month period. The investigators will conduct an effectiveness-implementation hybrid type 2 trial using a 3 (Region) x 2 (Setting) x 2 (Delivery Mode) factorial design. The long-term objective of this study is threefold: 1. To conduct an effectiveness-implementation hybrid 2 trial to test the effects of the PPP implementation strategies across different settings and modes of delivery among 600 NHPIs at risk for cardiometabolic-related conditions using an NHPI-approved and adapted evaluation framework. The investigators will also assess and compare the cost-effectiveness of the CHW-delivered PPP-Standard Facilitation and PPP-Enhanced Facilitation to support long-term sustainability. 2. To conduct a longitudinal Social Determinants of Health (SDOH) survey embedded within the trial to examine the reliability and validity of indices from 5 adapted SDOH instruments and to assess the associations between SDOH variables and chronic disease risk among NHPIs. 3. To implement and evaluate the contextually-based CHW training program on PPP delivery.

Waitlist Available
Has No Placebo

National Association of Pasifika Organizations (+1 Sites)

Joseph K Kaholokula, PhD

Image of Rush University Medical Center in Chicago, United States.

Food is Medicine for High Blood Pressure

18+
All Sexes
Chicago, IL

The goal of this clinical trial is to assess nutrition incentives and produce vouchers to measure the impacts of food insecurity-related chronic health conditions in adults with hypertension and/or diabetes. The main questions it aims to answer are: * Does participation increase fruit and vegetable consumption for participants? * Does participation reduce individual and household food insecurity? * Does participation reduce healthcare utilization and associated costs? * Does participation lead to improvements in diet-related health outcomes (e.g., hypertension, diabetes)? * Does participation support the local economy by increasing participant spending at local food vendors? Participants will: * Receive 6 months home delivered produce prescription boxes * Receive 6 months match of produce vouchers * Receive nutrition education and participate in Chronic Disease Self-Management classes

Waitlist Available
Has No Placebo

Rush University Medical Center

Traci Simmons, DrPHc, MPH

Have you considered Midamor clinical trials?

We made a collection of clinical trials featuring Midamor, we think they might fit your search criteria.
Go to Trials
Image of Mumford Professional Centre in Halifax, Canada.

Remote Monitoring for Cardiovascular Disease

18+
All Sexes
Halifax, Canada

The goal of this interventional study is to evaluate the implementation, usability, and clinical outcomes of a wearable medical-grade device in a virtual Cardiac Rehabilitation (CR) program, titled HEARTS in Sync. The question guiding this study is: Do patient clinical outcomes differ between those who use the CardioWatch 287-2 during the HEARTS in Sync program as compared to those who participate without using the CardioWatch 287-2? The comparison will happen between two non-randomized groups of patients who are enrolled in the HEARTS in Sync virtual CR program. The wearable device (CardioWatch 287-2), worn on patient's wrists, will provide clinicians with physiological information to better mirror the clinical oversight provided to an in-person CR program. Participants who choose to use the device will be asked to wear it daily. The clinical team will review weekly summary reports to help guide participant progress through the 13-week program. The primary objectives of this study are to: 1. Characterize participants (e.g., demographic health history, patient feedback) between those who choose to use the CardioWatch 287-2 device and those who do not. 2. Compare clinical outcomes between users and non-users of the device within the HEARTS in Sync program, by: 1. Tracking patient enrollment, attendance in virtual education sessions, and program completion rates, 2. Evaluating change in patient bloodwork outcomes, 3. Measuring change is physical ability, 4. Analyzing changes in eating behaviours, and 5. Examining quality of life using validated tools. 3. Asses the feasibility of the CardioWatch 287-2 for the HEARTS in Sync virtual CR program by: 1. Assessing device adherence 2. Reviewing patient feedback survey, and 3. Determining if clinician team were able to access and interpret data collected throughout the program The secondary objective of this study is to compare clinical outcomes of device users during the HEARTS in Sync program with patients who completed the on-site CR program. This research aims to better understand how a medical-grade device may improve virtual CR programming to extend clinical care to the community. As a result, this could lead to a more personalized care and better results for patients.

Waitlist Available
Has No Placebo

Mumford Professional Centre

Nicholas B Giacomantonio, Medical Doctor

Corsano Health B.V.

Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL

This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.

Waitlist Available
Has No Placebo

U Health (+1 Sites)

Ziad Zoghby, M.D., M.B.A.

Biobeat Technologies Ltd.

Have you considered Midamor clinical trials?

We made a collection of clinical trials featuring Midamor, we think they might fit your search criteria.
Go to Trials
Image of Virginia Commonwealth University in Richmond, United States.

Endovascular Treatment for Stroke

18+
All Sexes
Richmond, VA

Endovascular therapy (EVT) has proven to be more beneficial for patients with AIS caused by large vessel occlusions (LVO) than medical management alone. A recent meta-analysis of 5 RCTs showed that EVT significantly reduced disability at 90 days compared to medical management \[1\]. Despite its obvious benefits, patients may have neurological deterioration despite successful thrombectomy due to ischemia progression, intracranial hemorrhage, re-occlusion, or vasogenic edema. The incidence of early neurological deterioration (END) following EVT for acute stroke has been reported to be ranging from 14.1-35.2% with some studies defining END up to 7 days and some restricting the definition between 6-72 hours post thrombectomy. A small proportion of these patients, approximately 5.9-10.5%, experienced sICH following EVT. Whether END occurs due to ischemic or hemorrhagic it leads to worse outcomes.

Waitlist Available
Has No Placebo

Virginia Commonwealth University

Aarti Sarwal

Have you considered Midamor clinical trials?

We made a collection of clinical trials featuring Midamor, we think they might fit your search criteria.
Go to Trials